AI Article Synopsis
- Keratosis lichenoides chronica (KLC) is a rare skin condition featuring raised, rough papules that often form linear or reticular patterns, primarily affecting limbs and the trunk, with some facial involvement.
- Diagnoses are often delayed, but histological confirmation is required, and the condition affects individuals of all ages with a slight male predominance; about 25% of cases are in children.
- Current treatment options include phototherapy and systemic retinoids, which have shown effectiveness, while corticosteroids and other medications have proven ineffective.
Article Abstract
Keratosis lichenoides chronica (KLC) is a rare dermatological condition characterized by keratotic papules arranged in a parallel linear or reticular pattern and facial lesions resembling seborrheic dermatitis or rosacea. The clinical, histological and therapeutic information on 71 patients with KLC retrieved through a PubMed search plus one our new case were analyzed. KLC affects patients of all ages, with a modest male predominance. Pediatric cases represent about one quarter of patients. Diagnosis is usually delayed and histologically confirmed. All patients have thick, rough and scaly papules and plaques arranged in a linear or reticular pattern, on limbs (>80%) and trunk (about 60%). Face involvement is described in two-thirds of patients. Lesions are usually asymptomatic or mildly pruritic. Other manifestations, such as palmoplantar keratoderma, mucosal involvement, ocular manifestations, nail dystrophy, are reported in 20-30% of patients. Children present more frequently alopecia. No controlled trials are available. Results from small case series or single case reports show that the best treatment options are phototherapy and systemic retinoids, alone or in combination, with nearly half of patients reaching complete remission. Systemic corticosteroids as well as antibiotics and antimalarials are not effective.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/09546634.2015.1115818 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concurrent Eruptive Melanocytic Nevi and Multiple Keratoacanthomas Induced by Encorafenib.
Cureus
September 2024
Oncology, Biokliniki Athinon, Athens, GRC.
Article Synopsis
- - A case study discusses a 64-year-old male with metastatic colorectal cancer who developed severe itching and new skin lesions after treatment with encorafenib and panitumumab, medications targeting cancer pathways.
- - The patient showed a mix of skin lesions, including benign moles and keratoacanthomas, with further evaluation confirming a link between the skin reactions and the use of encorafenib, as validated by the Naranjo scale.
- - Stopping the medications led to significant improvement in skin lesions, highlighting the importance of ongoing skin assessments for patients on BRAF inhibitors to manage side effects effectively.
Comparative Analysis of AI Models for Atypical Pigmented Facial Lesion Diagnosis.
Bioengineering (Basel)
October 2024
Dermatology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy.
Article Synopsis
- Diagnosing atypical pigmented facial lesions (aPFLs) is difficult for dermatologists and crucial for patient care, as incorrect diagnoses can lead to mismanagement and delays in treatment.
- The study compared machine learning and deep learning models to improve diagnostic accuracy of aPFLs using 1197 dermoscopic images classified into seven categories, focusing on the potential role of AI in supporting clinicians.
- Results showed that while dermatologists were 71.2% accurate in identifying malignant versus benign lesions, their accuracy dropped to 42.9% when distinguishing among specific lesions, highlighting the complexity of aPFL evaluations.
Keratosis Lichenoides Chronica with Pulmonary Tuberculosis: A Possible Association.
Clin Exp Dermatol
October 2024
Era's Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India.
Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS database.
Heliyon
September 2024
Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330000, China.
Article Synopsis
- - The study aims to assess the risks associated with enfortumab vedotin (EV) for advanced bladder cancer using real-world data from the FDA's adverse event reporting system (FAERS) from early 2020 to early 2024.
- - Researchers conducted a detailed analysis of 7,449,181 FAERS case reports, identifying 1,617 EV-related adverse drug events (ADEs) and finding significant safety signals for rare conditions like lichenoid keratosis and small intestinal perforation.
- - The results mostly matched existing safety data, highlighting the importance of ongoing clinical monitoring for EV-related ADEs and the need for further research to confirm the newly discovered risks.
Oral Lichen Planus: A Narrative Review Navigating Etiologies, Clinical Manifestations, Diagnostics, and Therapeutic Approaches.
J Clin Med
September 2024
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah 11481, Saudi Arabia.
: Oral Lichen Planus (OLP) is a common immune-mediated inflammatory disorder affecting the oral mucosa, impacting 0.5% to 2% of the global population, primarily middle-aged women. Immunological dysregulation is a key factor in OLP's pathogenesis, involving CD4+ T helper and CD8+ T cytotoxic cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!